Liraglutide
Victoza · Saxenda
A once-daily GLP-1 receptor agonist with FDA approval for T2D and obesity, the predecessor to semaglutide with strong clinical evidence.
Half-Life
~13 hours
MW
3751.2 Da
Amino Acids
N/A
Evidence
High Evidence
Regulatory Status
FDA-approved (Victoza: T2D, Saxenda: obesity). Extensive clinical data.
In Plain English
The original once-daily GLP-1 injection — the predecessor to semaglutide. Lower dose treats diabetes (Victoza), higher dose treats obesity (Saxenda). It was the first GLP-1 drug proven to reduce heart attacks and strokes.
Overview
Liraglutide was among the first long-acting GLP-1 analogues approved for both T2D (Victoza) and obesity (Saxenda). While less potent than semaglutide for weight loss (~5-8%), it has the longest clinical track record in the GLP-1 class.
Common Formats
- Pre-filled injection pen (daily)
Storage Notes
Refrigerate 2-8°C before use. Room temperature up to 30 days.
Looking for multi-compound protocols?
Browse educational protocol discussions that include Liraglutide.
Related Compounds
Semaglutide
A GLP-1 receptor agonist with FDA approval for type 2 diabetes and obesity, demonstrating unprecedented weight loss results in clinical trials.
Tirzepatide
A dual GIP/GLP-1 receptor agonist with FDA approval showing up to 22% weight loss — superior to semaglutide in head-to-head trials.
Exenatide
The first GLP-1 receptor agonist approved by the FDA for T2D, derived from Gila monster venom with strong glucose-lowering and weight management effects.
Educational Disclaimer: All information on this page is for educational and research purposes only. This does not constitute medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional.